Engineered mixed oxide powders
Ceramic Fuel Cells has extensive know-how in ceramic powder production for applications such as; fuel cells, thermal barrier coatings, biomedical and dental implants and high temperature products such as thread guides and fibre optic connectors.
Can't differentiate between the two? Is he a novice?
That includes a vast amount of over the counter drugs like Tylenol as an example;
Read about Tylenol liver damage (acetaminophen) from accidentally taking too much of this drug, which can permanently damage the liver
Think about all the research testing which is required on every drug. Think about the requirements for liver tissue. Thank about Organovo :)
And you are like the bashers on every board. The ones who have no face but silly names and bS stories who we don't need to rationalIze to because you really don't want honesty or real answers. You just want to post more trash. Have a great life. Hopefully you won't ever need an Organovo product!
SO corroborated studies by various sources are meaningless and have nothing to do with Organovo? Ok you keep shorting. Are you about the average intelligence of all shorts who post such absurd irrational statements here? No problem LOL
My post is as rediculous as those of the bashers. Did I make my point?
Unique. Priceless. Intangible assets
“New areas of research in tissue engineering and regenerative medicine.”
Desktop 3-D printers can already pump out a toy trinket, gear set or even parts to make another printer. Medical researchers are also taking advantage of this accelerating technology to expand their options for regenerative medicine. Brian Derby, of the School of Materials at the University of Manchester in England, details the advances and challenges of this growing field in a new review paper published online November 15 in Science.
Researchers have made great strides in coaxing cells to grow over artificial, porous scaffolds that can then be implanted in the body to replace hard tissue, such as bone. Three years ago, doctors were able to coax stem cells to grow over bone scaffolds, which regenerated bone to implant into the face of a teenage boy, who had a genetic defect that left him without cheekbones.
But now, instead of relying on poured molds, foam designs or donated biological materials, researchers can print custom scaffold structures with biocompatible, biodegradable polymers. “These methods have allowed us to develop very complex scaffolds which better mimic the conditions inside the body,” Derby said in a prepared statement.
Engineers can carefully control the minute, internal structures of these porous scaffolds to best promote cellular growth. And these new printing methods also allow quick and cheap experiments that test various one-off designs.
You are playing with fire. Cash is king and will prevent you from being stopped out short term.
It is you who doesn't seem to understand. Do you know that
Organovo Partners With Autodesk Research to Develop 3D Bioprinting Software
SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, is working together with researchers at Autodesk, Inc., the leader in cloud-based design and engineering software, to create the first 3D design software for bioprinting.
The software, which will be used to control Organovo's NovoGen MMX bioprinter, will represent a major step forward in usability and functionality for designing three-dimensional human tissues, and has the potential to open up bioprinting to a broader group of users.
Organovo Provides Guidance on Upcoming Retail Investor Conference
SAN DIEGO, Nov. 20, 2013
SAN DIEGO, Nov. 20, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today provided guidance on topics to be discussed at an upcoming Retail Investor Conference on December 5, 2013.
Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Thursday, December 5, 2013 at 12:30pm ET, and investors can directly participate in this live, interactive online event. Investors will be invited to ask the company questions in real-time — both in the presentation hall as well as the company's "virtual trade booth."
At the conference, Organovo will provide guidance on several topics, including:
Product pipeline and revenue potential: As described previously in the company's presentations and investor communications, including the freely available Retail Investor Conference from September 12, 2013, the company plans to launch an initial 3D liver tissue assay product in 2014, followed by a series of additional tissue assay products. Based on market research, Organovo believes that each of the product opportunities it has identified can grow into the tens of millions in annual revenue and has a $100M+ addressable market, with an overall market opportunity of $500M across all tissue products by 2018. Beyond this market opportunity, defined by sales of current cell based models, also lies the opportunity to develop products and services for the multibillion dollar animal preclinical testing market for pharmaceutical, cosmetic, and environmental industries.
Partnership model revenues: As described previously, the company will discuss its partnership model revenue opportunities, targeting $10-30M in milestone payments and 3%-7% in future royalties per opportunity. Organovo will also review its existing agreements, includ
SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has been invited to present at the 24th Annual Oppenheimer Healthcare Conference, which will be held in New York December 10-11, 2013.
Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Wednesday, December 11, at 2:45pm ET.
The objective of the Oppenheimer 24th Annual Healthcare Conference is to provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry, including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers. The conference will be held at the Crowne Plaza Hotel – New York.